

Applicants: William R. Jacobs, Jr., Tsungda Hsu, Stoyan Bardanov,
Vasan Sambandamurthy and Sheldon Morris
Appl. No.: 10/542,958
Filed: January 30, 2007
page 2 of 5

Claim Amendments

A listing of the claims, including Claim 1 as currently amended, and new Claims 88 and 89 as added, is set forth below.

1. (Currently amended) A method for inoculating a an immunocompromised mammal against *Mycobacterium tuberculosis*, wherein the mammal does not have severe combined immune deficiency but is deficient in CD4⁺ lymphocytes or in CD8⁺ lymphocytes, the method comprising administering to the immunocompromised mammal an amount of an attenuated *M. tuberculosis* or *M. bovis* mycobacterium effective to confer protection against *Mycobacterium tuberculosis* in the mammal, wherein the attenuated mycobacterium has (i) a deletion of RD1 and is auxotrophic for pantothenate, or (ii) is auxotrophic for both lysine and pantothenate.

2-4. (Canceled)

5. (Original) The method of claim 1, wherein the attenuated mycobacterium is an *M. tuberculosis*.

6-7. (Canceled)

8. (Original) The method of claim 1, wherein the attenuated mycobacterium is an *M. bovis*.

9. (Canceled)

10. (Original) The method of claim 1, wherein the mammal is a human.

Applicants: William R. Jacobs, Jr., Tsungda Hsu, Stoyan Bardanov,
Vasan Sambandamurthy and Sheldon Morris
Appl. No.: 10/542,958
Filed: January 30, 2007
page 3 of 5

11-18. (Canceled)

19. (Previously Presented) The method of claim 1, wherein the RD1 deletion is a $\Delta panCD$ deletion.

20-40. (Canceled)

41. (Previously Presented) The method of claim 1, wherein the mammal is deficient in CD8⁺ lymphocytes.

42-86. (Canceled)

87. (Previously presented) The method of claim 1, wherein the mammal is deficient in CD4⁺ lymphocytes.

88. (New) The method of claim 1, wherein the attenuated mycobacterium has a deletion of RD1 and is auxotrophic for pantothenate.

89. (New) The method of claim 1, wherein the attenuated mycobacterium is auxotrophic for both lysine and pantothenate.